The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 3 randomized, controlled, open-label study of selinexor, bortezomib, and dexamethasone (SVd) versus bortezomib and dexamethasone (Vd) in patients with relapsed or refractory multiple myeloma (RRMM).
 
Sosana Delimpasi
No Relationships to Disclose
 
Ludek Pour
No Relationships to Disclose
 
Holger W Auner
No Relationships to Disclose
 
Meletios A. Dimopoulos
Honoraria - Amgen; Bristol-Myers Squibb; Celgene; Genesis Pharmaceuticals; Janssen-Cilag; Novartis; Takeda
Consulting or Advisory Role - Amgen; Celgene; Janssen-Cilag; Takeda
Research Funding - Amgen (Inst); Janssen-Cilag (Inst)
Travel, Accommodations, Expenses - Amgen; Genesis Pharmaceuticals; Janssen-Ortho
 
Alon Rappaport
Employment - Karyopharm Therapeutics
Stock and Other Ownership Interests - Karyopharm Therapeutics
 
Lisa Fortin
Employment - Karyopharm Therapeutics
Stock and Other Ownership Interests - Karyopharm Therapeutics
 
Jatin J. Shah
Employment - Karyopharm Therapeutics
Leadership - Karyopharm Therapeutics
Stock and Other Ownership Interests - Karyopharm Therapeutics
 
Sharon Shacham
Employment - Karyopharm Therapeutics
Leadership - Karyopharm Therapeutics
Stock and Other Ownership Interests - Karyopharm Therapeutics
 
Michael G. Kauffman
Employment - Karyopharm Therapeutics
Leadership - Karyopharm Therapeutics
Stock and Other Ownership Interests - Karyopharm Therapeutics
 
Nizar J. Bahlis
No Relationships to Disclose